| Trial ID: | L2472 |
| Source ID: | NCT06046560
|
| Associated Drug: |
Sglt2 Inhibitor, Glp-1 Ra
|
| Title: |
Diabetes Remote Intervention to improVe Use of Evidence-based Medications
|
| Acronym: |
DRIVE
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT06046560/results
|
| Conditions: |
Cardiovascular Diseases|Diabetes
|
| Interventions: |
DRUG: SGLT2 inhibitor, GLP-1 RA|BEHAVIORAL: Education-First
|
| Outcome Measures: |
Primary: Number of Patients With Prescriptions of SGLT2i or GLP1-RA at Any Time, Number of patients with prescriptions of SGLT2i or GLP1-RA at any time, Any time between 0-months (baseline) to 6-months following enrollment | Secondary: Number of Patients With Prescriptions of SGLT2i or GLP1-RA at 2-months, Number of patients with prescriptions of SGLT2i or GLP1 RA at 2-months, 2-months following enrollment|Number of Patients With Prescriptions of SGLT2i or GLP1-RA at 6-months, Number of patients with prescriptions of SGLT2i or GLP1-RA at 6-months, At 6-months following enrollment|Change in Short-form Patient Activation Measure (PAM), Change in Short-form Patient Activation Measure (PAM) The score is measured on a 0.0 - 4.0 point scale and indicates participants' relationships with and understanding of their health care. A higher value represents a better outcome. This measure indicates the change in participants' scores from the point of enrollment (0-months) to program completion (6-months). 0.0 - 1.0 (Disengaged \& Overwhelmed) 1.1 - 2.0 (Becoming Aware But Still Struggling) 2.1 - 3.0 (Taking Action \& Gaining Control) 3.1 - 4.0 (Maintaining Behaviors \& Pushing Further), From 0-months (baseline) to 6-months following enrollment | Other: Change in Body Weight (kg), Change in body weight (kg), From 0-months (baseline) to 6-months following enrollment|Change in Body Weight (%), Change in body weight (%), From 0-months (baseline) to 6-months following enrollment|Change in Laboratory Measured HbA1c, Change in laboratory measured HbA1c, From 0-months (baseline) to 6-months following enrollment
|
| Sponsor/Collaborators: |
Sponsor: Brigham and Women's Hospital | Collaborators: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
200
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION
|
| Start Date: |
2021-03-22
|
| Completion Date: |
2023-07-25
|
| Results First Posted: |
2024-10-23
|
| Last Update Posted: |
2024-10-23
|
| Locations: |
Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT06046560
|
